By Jeannie O'Sullivan ( December 3, 2015, 4:04 PM EST) -- AstraZeneca AB blasted Mylan Laboratories Ltd.'s contention that New Jersey is the wrong venue for a patent infringement lawsuit over AstraZeneca's breast cancer drug, arguing Wednesday that it was the generic-drug maker's Garden State subsidiary that filed the application to market its version of the drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.